Mode
Text Size
Log in / Sign up

Fibromyalgia as an oncology comorbidity increases symptom burden and impairs treatment adherenceFibromyalgia makes managing cancer pain more difficult for patients

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Recognize that fibromyalgia as a comorbidity may increase symptom burden and lead to premature discontinuation of therapies.

This systematic review synthesizes evidence from 11 studies regarding the prevalence and clinical impact of fibromyalgia as a comorbidity in adult patients with cancer or cancer-related pain. The authors conclude that while fibromyalgia does not increase cancer risk, it significantly contributes to pain amplification and results in a higher symptom burden for these patients.

Key findings indicate that fibromyalgia is associated with reduced health-related quality of life (HRQoL) and impaired treatment adherence. Specifically, the review notes that pre-existing nociplastic pain features are associated with premature discontinuation of oncological therapies, particularly endocrine treatments.

The authors note several limitations, including heterogeneous populations and study designs which precluded a quantitative synthesis. Furthermore, evidence in oncology populations remains limited, and the findings are subject to moderate to high risk of bias due to confounding factors. High-quality longitudinal studies are required to clarify causal associations. Clinically, these findings suggest that fibromyalgia is a relevant comorbidity requiring further investigation and evidence-based management strategies for patients experiencing cancer-related pain.

How this fits prior evidence

This systematic review addresses a gap in the understanding of patient comorbidities by identifying how fibromyalgia impacts outcomes in oncology. While previous coverage noted that e-health self-management interventions improve quality of life in cancer patients, this finding highlights how specific comorbidity features like nociplastic pain can negatively impact HRQoL and treatment adherence.

Managing cancer is already a heavy burden, but it becomes even more complex when a patient also lives with fibromyalgia. This condition can significantly amplify how the body perceives pain. When these two conditions exist together, patients often experience a much heavier load of symptoms and a lower quality of life.

Research involving 11 studies shows that having fibromyalgia does not increase the risk of developing cancer. However, it does make managing the side effects of cancer treatment harder. Specifically, patients with certain types of chronic pain features were more likely to stop their cancer treatments early, especially hormone-based therapies.

Because the evidence is still limited and some studies had a high risk of bias, doctors need more high-quality data to create perfect management plans. For now, it highlights why recognizing these overlapping conditions is vital for helping patients stay on their treatment paths.

What this means for you:
Fibromyalgia can amplify cancer pain and lead to earlier stops in cancer treatments like hormone therapy.

Common questions

Does having fibromyalgia increase the risk of getting cancer?

No, the research shows that having fibromyalgia does not increase a person's risk of developing cancer. While it makes managing symptoms and treatment much harder, it does not change the underlying risk of the cancer itself.

How does fibromyalgia affect cancer treatment?

Fibromyalgia can lead to a higher burden of symptoms and lower quality of life for patients. It also makes it harder to stick to treatment plans. Specifically, certain pain features associated with fibromyalgia were linked to the premature stopping of cancer treatments, especially endocrine therapies.

Why is it harder for these patients to manage pain?

Fibromyalgia contributes significantly to pain amplification. This means the body's way of processing pain signals becomes more intense. When combined with cancer, this makes the overall symptom burden much heavier and can make it difficult for patients to tolerate their medications.

Study Details

Study typeMeta analysis
EvidenceLevel 1
PublishedJun 2026
View Original Abstract ↓
IntroductionIn oncology, fibromyalgia (FM) is increasingly recognized as a clinically relevant comorbidity, as cancer patients frequently present overlapping symptoms such as pain, fatigue, and sleep disturbances, complicating clinical assessment and management. Moreover, anticancer treatments may trigger or exacerbate FM-like symptoms. This systematic review aimed to synthesize the available evidence on FM in oncological patients, focusing on prevalence, clinical characteristics, and its impact on pain perception, Health-Related Quality of Life (HRQoL), and treatment adherence.MethodsA comprehensive literature search was conducted in PubMed, Embase, and Scopus, including studies published from 2014 to 2024. Eligible studies, in accordance with PRISMA guidelines, included observational, cross-sectional and interventional designs involving adult patients with FM in the context of cancer or cancer-related pain. Conversely, studies not assessing FM in relation to cancer or cancer-related pain were excluded. Risk of bias was evaluated using ROBINS-I tool and the RoB 2 tool.ResultsA total of 11 studies were included, encompassing heterogeneous populations and study designs, thereby precluding a quantitative synthesis of the literature. Overall, evidence suggests that FM did not increase cancer risk but significantly contributes to pain amplification, higher symptom burden, reduced HRQoL, and impaired treatment adherence. Pre-existing nociplastic pain features were associated with premature discontinuation of oncological therapies, particularly endocrine treatments. The substantial overlap between FM-related and cancer-related symptoms may represent a major diagnostic challenge in clinical practice.DiscussionThis review highlights a substantial research gap, as evidence in oncology populations remains limited and is affected by moderate to high risk of bias, partly due to confounding factors. Nevertheless, FM appears to be a relevant comorbidity in oncology, warranting further investigation. High-quality longitudinal studies are needed to clarify causal associations and support evidence-based management.Systematic Review RegistrationThe protocol for this systematic review was retrospectively registered on the Open Science Framework (OSF; https://doi.org/10.17605/OSF.IO/X5N29).
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.